ADAR1 Capital Management »

Royalty Pharma shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Royalty Pharma (RPRX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Royalty Pharma

Tip: Access up to 7 years of quarterly data

All positions including Royalty Pharma held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Royalty Pharma by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $22M 721k 30.37
2023-12-31 $37M 1.3M 28.09

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Royalty Pharma

Morgan Stanley
Vanguard Group
BlackRock
BlackRock
Baillie Gifford & Co
Viking Global Investors
Swedbank AB
State Street Corporation
Geode Capital Management
Amundi
Siguler Guff Advisers
Charles Schwab Investment Management
Northern Trust
New South Capital Management
Deutsche Bank Aktiengesellschaft

View all funds holding Royalty Pharma